{
    "xml": "<topic id=\"PHP3075\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/pramipexole\" basename=\"pramipexole\" title=\"PRAMIPEXOLE\">\n<title>PRAMIPEXOLE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_881\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/pramipexole\">Pramipexole</xref>\n</p>\n<data name=\"vtmid\">108471007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_157437168\" title=\"Dopamine receptor agonists\">Dopamine receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP74479\" outputclass=\"indicationsAndDose\" rev=\"1.33\" parent=\"/drugs/pramipexole\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Parkinson's disease, used alone or as an adjunct to co-beneldopa or co-careldopa</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 88&#8239;micrograms 3 times a day, increased if tolerated to 350&#8239;micrograms 3 times a day, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 180&#8239;micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3&#8239;mg per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 260&#8239;micrograms once daily, increased to 1.05&#8239;mg once daily, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 520&#8239;micrograms every 1&#8239;week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Restless legs syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 88&#8239;micrograms once daily, dose to be taken 2&#8211;3 hours before bedtime, dose to be increased by doubling dose every 4&#8211;7 days, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540&#8239;micrograms per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>Doses and strengths are stated in terms of pramipexole (base).</p>\n<p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:</p>\n<p>88&#8239;micrograms base &#8801; 125&#8239;micrograms salt;</p>\n<p>180&#8239;micrograms base &#8801; 250&#8239;micrograms salt;</p>\n<p>350&#8239;micrograms base &#8801; 500&#8239;micrograms salt;</p>\n<p>700&#8239;micrograms base &#8801; 1&#8239;mg salt.</p>\n<p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for modified-release preparations are as follows:</p>\n<p>260&#8239;micrograms base &#8801; 375&#8239;micrograms salt;</p>\n<p>520&#8239;micrograms base &#8801; 750&#8239;micrograms salt;</p>\n<p>1.05&#8239;mg base &#8801; 1.5&#8239;mg salt;</p>\n<p>1.57&#8239;mg base &#8801; 2.25&#8239;mg salt;</p>\n<p>2.1&#8239;mg base &#8801; 3&#8239;mg salt;</p>\n<p>2.62&#8239;mg base &#8801; 3.75&#8239;mg salt;</p>\n<p>3.15&#8239;mg base &#8801; 4.5&#8239;mg salt.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74493\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/pramipexole\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Impulse control disorders</p>\n<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74503\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/pramipexole\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Psychotic disorders</ph>; <ph outputclass=\"caution\">risk of visual disorders (ophthalmological testing recommended)</ph>; <ph outputclass=\"caution\">severe cardiovascular disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74475\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/pramipexole\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (pramipexole).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74457\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/pramipexole\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">decreased appetite</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyskinesia</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hyperkinesia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">postural hypotension</ph>; <ph outputclass=\"sideEffect\">restlessness</ph>; <ph outputclass=\"sideEffect\">sleep disturbances</ph>; <ph outputclass=\"sideEffect\">sudden onset of sleep</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">weight changes</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Amnesia</ph>; <ph outputclass=\"sideEffect\">binge eating</ph>; <ph outputclass=\"sideEffect\">cardiac failure</ph>; <ph outputclass=\"sideEffect\">compulsive behaviour</ph>; <ph outputclass=\"sideEffect\">delusion</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">hiccups</ph>; <ph outputclass=\"sideEffect\">paranoia</ph>; <ph outputclass=\"sideEffect\">pneumonia</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">syncope</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Paradoxical worsening of restless legs syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74470\" outputclass=\"pregnancy\" parent=\"/drugs/pramipexole\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if potential benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74507\" outputclass=\"breastFeeding\" parent=\"/drugs/pramipexole\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>May suppress lactation; avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74463\" outputclass=\"renalImpairment\" parent=\"/drugs/pramipexole\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>For <i>immediate-release</i> tablets in Parkinson's disease, initially 88&#8239;micrograms twice daily (max. 1.57&#8239;mg daily in 2 divided doses) if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; initially 88&#8239;micrograms once daily (max. 1.1&#8239;mg once daily) if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR.</p>\n<p>For <i>immediate-release</i> tablets in restless legs syndrome, reduce dose if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>For <i>modified-release</i> tablets, initially 260&#8239;micrograms on alternate days if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, increased to 260&#8239;micrograms once daily after 1 week, further increased if necessary by 260&#8239;micrograms daily at weekly intervals to max. 1.57&#8239;mg daily.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For <i>modified-release</i> tablets, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74447\" outputclass=\"monitoringRequirements\" parent=\"/drugs/pramipexole\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Risk of postural hypotension (especially on initiation)&#8212;monitor blood pressure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74450\" outputclass=\"treatmentCessation\" rev=\"1.8\" parent=\"/drugs/pramipexole\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74468\" outputclass=\"patientAndCarerAdvice\" rev=\"1.13\" parent=\"/drugs/pramipexole\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p outputclass=\"title\">Sudden onset of sleep</p>\n<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p>\n<p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p>\n<p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypotensive reactions</p>\n<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3075-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pramipexole\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77137\" title=\"Tablet\" namespace=\"/drugs/pramipexole/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77144\" title=\"Modified-release tablet\" namespace=\"/drugs/pramipexole/modified-release-tablet\">Modified-release tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"1\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_881\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/pramipexole\" title=\"Pramipexole\" count=\"1\" rel=\"link\">Pramipexole</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77137\" namespace=\"/drugs/pramipexole/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77144\" namespace=\"/drugs/pramipexole/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n</links>\n</topic>",
    "id": "PHP3075",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/pramipexole",
    "basename": "pramipexole",
    "title": "PRAMIPEXOLE",
    "interactants": [
        {
            "id": "bnf_int_881",
            "label": "Pramipexole"
        }
    ],
    "vtmid": "108471007",
    "drugClassification": [
        "Dopamine receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Parkinson's disease, used alone or as an adjunct to co-beneldopa or co-careldopa",
                        "html": "Parkinson's disease, used alone or as an adjunct to co-beneldopa or co-careldopa"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 88 micrograms 3 times a day, increased if tolerated to 350 micrograms 3 times a day, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 180 micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3 mg per day.",
                        "html": "<p>Initially 88&#8239;micrograms 3 times a day, increased if tolerated to 350&#8239;micrograms 3 times a day, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 180&#8239;micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 260 micrograms once daily, increased to 1.05 mg once daily, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 520 micrograms every 1 week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15 mg per day.",
                        "html": "<p>Initially 260&#8239;micrograms once daily, increased to 1.05&#8239;mg once daily, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 520&#8239;micrograms every 1&#8239;week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Restless legs syndrome",
                        "html": "Restless legs syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using immediate-release medicines"
                    ],
                    "textContent": "By mouth using immediate-release medicines",
                    "html": "By mouth using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 88 micrograms once daily, dose to be taken 2&#8211;3 hours before bedtime, dose to be increased by doubling dose every 4&#8211;7 days, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540 micrograms per day.",
                        "html": "<p>Initially 88&#8239;micrograms once daily, dose to be taken 2&#8211;3 hours before bedtime, dose to be increased by doubling dose every 4&#8211;7 days, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540&#8239;micrograms per day.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Doses and strengths are stated in terms of pramipexole (base).\n\nEquivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:\n\n88 micrograms base &#8801; 125 micrograms salt;\n\n180 micrograms base &#8801; 250 micrograms salt;\n\n350 micrograms base &#8801; 500 micrograms salt;\n\n700 micrograms base &#8801; 1 mg salt.\n\nEquivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for modified-release preparations are as follows:\n\n260 micrograms base &#8801; 375 micrograms salt;\n\n520 micrograms base &#8801; 750 micrograms salt;\n\n1.05 mg base &#8801; 1.5 mg salt;\n\n1.57 mg base &#8801; 2.25 mg salt;\n\n2.1 mg base &#8801; 3 mg salt;\n\n2.62 mg base &#8801; 3.75 mg salt;\n\n3.15 mg base &#8801; 4.5 mg salt.",
                "html": "<p>Doses and strengths are stated in terms of pramipexole (base).</p><p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:</p><p>88&#8239;micrograms base &#8801; 125&#8239;micrograms salt;</p><p>180&#8239;micrograms base &#8801; 250&#8239;micrograms salt;</p><p>350&#8239;micrograms base &#8801; 500&#8239;micrograms salt;</p><p>700&#8239;micrograms base &#8801; 1&#8239;mg salt.</p><p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for modified-release preparations are as follows:</p><p>260&#8239;micrograms base &#8801; 375&#8239;micrograms salt;</p><p>520&#8239;micrograms base &#8801; 750&#8239;micrograms salt;</p><p>1.05&#8239;mg base &#8801; 1.5&#8239;mg salt;</p><p>1.57&#8239;mg base &#8801; 2.25&#8239;mg salt;</p><p>2.1&#8239;mg base &#8801; 3&#8239;mg salt;</p><p>2.62&#8239;mg base &#8801; 3.75&#8239;mg salt;</p><p>3.15&#8239;mg base &#8801; 4.5&#8239;mg salt.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Impulse control disorders",
                "textContent": "Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.",
                "html": "<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Psychotic disorders",
                "html": "Psychotic disorders"
            },
            {
                "type": "cautions",
                "textContent": "risk of visual disorders (ophthalmological testing recommended)",
                "html": "risk of visual disorders (ophthalmological testing recommended)"
            },
            {
                "type": "cautions",
                "textContent": "severe cardiovascular disease",
                "html": "severe cardiovascular disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (pramipexole).",
                "html": "<p>Appendix 1 (pramipexole).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Confusion",
                        "html": "Confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "decreased appetite",
                        "html": "decreased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyskinesia",
                        "html": "dyskinesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperkinesia",
                        "html": "hyperkinesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "postural hypotension",
                        "html": "postural hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "restlessness",
                        "html": "restlessness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sleep disturbances",
                        "html": "sleep disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sudden onset of sleep",
                        "html": "sudden onset of sleep",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight changes",
                        "html": "weight changes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Amnesia",
                        "html": "Amnesia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "binge eating",
                        "html": "binge eating",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cardiac failure",
                        "html": "cardiac failure",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "compulsive behaviour",
                        "html": "compulsive behaviour",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "delusion",
                        "html": "delusion",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hiccups",
                        "html": "hiccups",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "paranoia",
                        "html": "paranoia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pneumonia",
                        "html": "pneumonia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Paradoxical worsening of restless legs syndrome",
                        "html": "Paradoxical worsening of restless legs syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if potential benefit outweighs risk&#8212;no information available.",
                "html": "<p>Use only if potential benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "May suppress lactation; avoid&#8212;present in milk in animal studies.",
                "html": "<p>May suppress lactation; avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "For immediate-release tablets in Parkinson's disease, initially 88 micrograms twice daily (max. 1.57 mg daily in 2 divided doses) if eGFR 20&#8211;50 mL/minute/1.73 m2; initially 88 micrograms once daily (max. 1.1 mg once daily) if eGFR less than 20 mL/minute/1.73 m2. If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR.\n\nFor immediate-release tablets in restless legs syndrome, reduce dose if eGFR less than 20 mL/minute/1.73 m2.\n\nFor modified-release tablets, initially 260 micrograms on alternate days if eGFR 30&#8211;50 mL/minute/1.73 m2, increased to 260 micrograms once daily after 1 week, further increased if necessary by 260 micrograms daily at weekly intervals to max. 1.57 mg daily.",
                "html": "<p>For <i>immediate-release</i> tablets in Parkinson's disease, initially 88&#8239;micrograms twice daily (max. 1.57&#8239;mg daily in 2 divided doses) if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; initially 88&#8239;micrograms once daily (max. 1.1&#8239;mg once daily) if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR.</p><p>For <i>immediate-release</i> tablets in restless legs syndrome, reduce dose if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>modified-release</i> tablets, initially 260&#8239;micrograms on alternate days if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, increased to 260&#8239;micrograms once daily after 1 week, further increased if necessary by 260&#8239;micrograms daily at weekly intervals to max. 1.57&#8239;mg daily.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For modified-release tablets, avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>For <i>modified-release</i> tablets, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Risk of postural hypotension (especially on initiation)&#8212;monitor blood pressure.",
                "html": "<p>Risk of postural hypotension (especially on initiation)&#8212;monitor blood pressure.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.",
                "html": "<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "title": "Sudden onset of sleep",
                "textContent": "Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.\n\nPatients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.\n\nManagement of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.",
                "html": "<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>"
            },
            {
                "type": "adviceAroundMissedDoses",
                "title": "Hypotensive reactions",
                "textContent": "Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.",
                "html": "<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77137",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77144",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_881",
                "label": "Pramipexole",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77137",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77144",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    }
}